PetDx
PetDx is a veterinary molecular diagnostics company that develops and commercializes OncoK9, a proprietary liquid biopsy assay for early cancer detection in dogs, serving veterinary clinics and pet owners via a distributor network.
- Company typePrivate
- Founded2019
- HeadquartersLa Jolla, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What PetDx does
PetDx is a veterinary molecular diagnostics company founded in 2019 and headquartered in La Jolla, California, focused on the early detection of cancer in dogs. The company develops and commercializes OncoK9, a proprietary liquid biopsy assay that analyzes genomic markers in canine blood samples to identify cancer signals non-invasively. The core product is positioned as an alternative to traditional surgical biopsy for initial cancer screening, with stated sensitivity for early-stage detection in dogs.
PetDx sells its diagnostic testing services primarily to veterinary clinics and animal hospitals, which order and administer the OncoK9 test for canine patients; pet owners are an indirect secondary segment accessed via veterinary referral. Revenue is generated through one-time testing fees on a license-style basis, with pricing not publicly disclosed. Distribution occurs through direct sales to veterinary practices and a global distributor network intended to broaden reach into additional clinics. The company is led by a co-founder-heavy management team spanning medical (Andi Flory, CMO), scientific (Dana Tsui, CSO), technology (Ilya Chorny, CTO), and operational/commercial functions, with Alejandro Bernal serving as CEO and President.
The company has raised approximately $72 million across two disclosed funding rounds: a $10M Series A in June 2020 led by Friedman BioVentures with Petco and TCA Venture Group, and a $62M Series B in December 2021 led by Longview Asset Management with participation from Aperture Venture Partners, Declaration Partners, Friedman BioVentures, K4 Group, LabCorp, Torch Capital, and Valor Equity Partners. Series B proceeds were earmarked for OncoK9 expansion, R&D acceleration, testing capacity scaling, and strengthening clinic and distributor partnerships. The company remains privately held with no disclosed revenue.
PetDx firmographics
Firmographics- Name
- PetDx
- Website
- https://petdx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- PetDx is a veterinary molecular diagnostics company that develops and commercializes OncoK9, a proprietary liquid biopsy assay for early cancer detection in dogs, serving veterinary clinics and pet owners via a distributor network.
- Ownership category
- akta.pro rank
PetDx industry classification
Industry- Product category
- Veterinary Diagnostic Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE)
- akta.pro secondary industry
- Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry) (HLAMADAJ)
Keywords
Where PetDx is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Markets served
PetDx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Veterinary Diagnostic Testing Services: PetDx generates revenue through its OncoK9 cancer detection test sold to veterinary clinics and potentially directly to pet owners through veterinary referral.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
PetDx product offering
Product offeringCore offering
PetDx develops and commercializes the OncoK9 cancer detection assay, a non-invasive blood-based liquid biopsy test designed for early detection of cancer in dogs. The assay analyzes genomic markers from a canine blood sample to identify cancer signals, providing veterinarians with a screening tool that can be used either in higher-risk breeds or for pets showing concerning symptoms. PetDx delivers the test through veterinary clinics and a distributor network.
Product overview
PetDx is a veterinary diagnostics company that offers a focused portfolio centered on canine cancer detection. The company's primary product is the OncoK9 assay, a blood-based test designed to detect cancer in dogs. The company uses this technology to provide diagnostic services to veterinary clinics and aims to expand testing capacity and strengthen partnerships with clinics and distributors.
Differentiator
Problem solved
Functional benefit
Brands
- OncoK9: Cancer detection assay for canine cancer screening
Companies that use PetDx
Customer profileSegments2 records
Ideal customer profiles2 records
PetDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PetDx partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights5 records
PetDx competitors and assessment
Company assessmentBroad incumbents
- IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company, offering reference lab services, in-clinic analyzers, and a broad menu of tests across species. It is a broad incumbent in the same veterinary diagnostics category in which PetDx operates, with established distribution into virtually every US veterinary practice.
- Antech Diagnostics: Antech is a leading veterinary reference laboratory network, owned by Mars Petcare, serving veterinary clinics with routine and specialty diagnostics. It overlaps directly with PetDx on the canine cancer screening use case and benefits from deep clinic relationships and bundled test menus.
- Zoetis Diagnostics: Zoetis is the largest global animal health company and offers diagnostic products (e.g., Vetscan) plus genetic testing (via the Basepaws acquisition). It is a broad incumbent competing for veterinary diagnostic spend, including genetic and specialty testing that overlaps with PetDx's molecular approach.
Direct peers
- Embark Veterinary: Embark is a canine genetic testing company offering DNA-based health and breed tests. While focused on inherited disease and breed genetics rather than cancer liquid biopsy, Embark is a direct peer in canine molecular diagnostics sold through breeders, owners, and veterinary channels.
- Wisdom Panel (Wisdom Health): Wisdom Panel, part of Mars Petcare, is a leading canine and feline genetic testing brand. It is a direct peer in companion-animal molecular diagnostics, with overlapping distribution through veterinary clinics and direct-to-consumer channels.
- Basepaws (Zoetis): Basepaws provides feline and canine genetic and oral-health screening tests and is now part of Zoetis. It is a direct peer offering molecular diagnostics for companion animals, with comparable product positioning around early detection of disease risk.
Emerging players
- Paw Print Genetics: Paw Print Genetics offers genetic testing for hereditary diseases and traits across multiple companion animal species. It is an emerging player in veterinary molecular diagnostics with overlapping technology (DNA-based assays) and channel (veterinary clinics, breeders), but does not currently focus on liquid-biopsy cancer detection.
- Volition Veterinary: Volition Veterinary is developing blood-based nucleomics tests for cancer and other conditions in companion animals. It is an emerging peer pursuing liquid-biopsy cancer diagnostics in dogs, with overlapping product concept and veterinary channel strategy.
Others
- Labcorp (LabCorp Drug Development / Oncology): LabCorp is a strategic investor in PetDx and a leading human clinical and anatomic pathology lab with extensive oncology diagnostics capabilities. It is a thematically related partner that provides infrastructure, scientific, and channel know-how transferable to veterinary oncology.
- Petco Health and Wellness: Petco is both an investor in PetDx and a leading US pet specialty retailer with growing veterinary services (Vital Care, Thrive). It is a strategic ecosystem participant that can serve as a distribution and awareness channel for canine cancer screening.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
PetDx social profiles
Digital presencePetDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
PetDx leadership team
Management profileNumber of profiles
Profiles9 records
PetDx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PetDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PetDx
What does PetDx do?
PetDx develops and commercializes the OncoK9 cancer detection assay, a non-invasive blood-based liquid biopsy test designed for early detection of cancer in dogs. The assay analyzes genomic markers from a canine blood sample to identify cancer signals, providing veterinarians with a screening tool that can be used either in higher-risk breeds or for pets showing concerning symptoms. PetDx delivers the test through veterinary clinics and a distributor network.
Is PetDx a public or private company?
PetDx is a private company. It is classified as venture growth investor backed and is currently operating.
When was PetDx founded?
PetDx was founded in 2019. It employs 51 to 100 people.
Where is PetDx based?
PetDx is headquartered in La Jolla, United States, in the North America region.
How does PetDx make money?
One revenue line is on record: veterinary Diagnostic Testing Services.
Who are PetDx's main competitors?
Broad incumbents on record are IDEXX Laboratories, Antech Diagnostics and Zoetis Diagnostics. Direct peers are Embark Veterinary, Wisdom Panel (Wisdom Health) and Basepaws (Zoetis). Emerging players are Paw Print Genetics and Volition Veterinary. Others are Labcorp (LabCorp Drug Development / Oncology) and Petco Health and Wellness.
Does PetDx have an API?
No public API is recorded for PetDx.
What industry is PetDx in?
PetDx's product category is Veterinary Diagnostic Services. Its primary akta.pro industry code is HLAMADAE, Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology), with a secondary code of HLAMADAJ, Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry). Its NAICS code is 621511 and its SIC code is 8071.